Riddle et al developed a schedule for titrating insulin doses in type 2 diabetic that would achieve a given target fasting plasma glucose ("treat-to-target"). This can result in effective insulin therapy while minimizing the risk of adverse side effects. The authors are from the Insulin Glargine 4002 Study Investigators.
